Table 3.
Participant characteristics and adjusted risk factors associated with TPT loss to follow-up*
| Total (N=1107) N (%)† |
TPT completed (N=892) N (%)‡ |
LTFU (N=215) N (%)‡ |
aHR of LTFU (95% CI) |
P value§ | |
| TPT regimen | |||||
| 9H | 995 (89.9) | 796 (80.0) | 199 (20.0) | Ref | |
| 3HR | 112 (10.1) | 96 (85.7) | 16 (14.3) | 3.83 (1.49 to 9.84) | 0.005 |
| Sex | |||||
| Female | 645 (58.3) | 512 (79.4) | 133 (20.6) | Ref | |
| Male | 462 (41.7) | 380 (82.3) | 082 (17.8) | 1.02 (0.94 to 1.11) | 0.608 |
| Age | |||||
| <15 years | 86 (7.8) | 72 (83.7) | 14 (16.3) | 0.63 (0.22 to 1.79) | 0.390 |
| 15–29 years | 116 (10.5) | 90 (77.6) | 26 (22.4) | 1.71 (0.88 to 3.35) | 0.116 |
| 30–44 years | 249 (22.5) | 195 (78.3) | 54 (21.7) | Ref | |
| 45–59 years | 426 (38.5) | 354 (83.1) | 72 (16.9) | 0.97 (0.56 to 1.69) | 0.911 |
| ≥60 years | 230 (20.8) | 181 (78.7) | 49 (21.3) | 1.14 (0.56 to 2.32) | 0.723 |
| Median age (IQR) | 50 (35–58) | 50 (35–58) | 49 (35–59) | ||
| Screening location | |||||
| Community screening event | 627 (56.6) | 523 (83.4) | 104 (16.6) | Ref | |
| Primary care centre | 480 (43.4) | 369 (76.9) | 111 (23.1) | 1.19 (0.62 to 2.30) | 0.593 |
| Target group | |||||
| Household and close contacts | 585 (52.9) | 458 (78.3) | 127 (21.7) | 1.03 (0.75 to 1.39) | 0.874 |
| Vulnerable community members | 470 (42.5) | 408 (86.8) | 62 (13.2) | Ref | |
| Healthcare workers | 52 (4.7) | 26 (50.0) | 26 (50.0) | 1.38 (1.25 to 1.53) | <0.001 |
| Urbanisation | |||||
| Urban | 729 (65.9) | 598 (82.0) | 131 (18.0) | Ref | |
| Periurban | 378 (34.2) | 294 (77.8) | 84 (22.2) | 1.00 (0.58 to 1.73) | 0.990 |
| Diabetes mellitus | |||||
| No/unknown | 1065 (96.2) | 859 (80.7) | 206 (19.3) | Ref | |
| Yes | 42 (3.8) | 33 (78.6) | 9 (21.4) | 0.74 (0.18 to 3.11) | 0.679 |
| History of TB | |||||
| No/unknown | 1096 (99.0) | 883 (80.6) | 213 (19.4) | Ref | |
| Yes | 11 (1.0) | 9 (81.8) | 2 (18.2) | 1.03 (0.14 to 7.63) | 0.980 |
*Model stratified by health insurance and residency status, so these parameters were excluded; parameters of sex and target group fitted as time-varying covariates; includes a total of 8211 person-months.
†Per cent of total.
‡Per cent of row total.
§Wald test.
aHR, adjusted HR; 9H, 9 months of daily isoniazid; 3HR, 3 months of daily isoniazid and rifampicin; LTFU, loss to follow-up; TB, tuberculosis; TPT, TB preventive therapy.